Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations

Immunology

Volumn 115, Issue 1, 2005, Pages 136-149

  Cheng, Wen Fang ^a   Lee, Chien Nan ^a   Su, Yi Ning ^a   Chang, Ming Cheng ^a   Hsiao, Wen Chun ^a   Chen, Chi An ^a   Hsieh, Chang Yao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cervical cancer; Cytotoxic T cell; ELISA ELISPOT; Human leukocyte antigen; Human papillomavirus

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HAPLOTYPES; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; UTERINE CERVICAL NEOPLASMS;

EID: 17844404289     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02126.x     Document Type: Article

References (43)

1. Chen TM, Chen CA, Wu CC, Huang SC, Chang CF, Hsieh CY. The genotypes and prognostic significance of human papilloma-viruses in cervical cancer. Int J Cancer 1994; 57:181-4.
2. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986; 67:665-9.
3. Rellihan MA, Dooley DP, Burke TW, Berkland ME, Longfield RN. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 1990; 36:435-8.
4. Penn I. Second malignant neoplasms associated with immunosuppressive medications. Cancer 1976; 37:1024-32.
5. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88:110-4.
6. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August T, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6.
7. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, Ling M, Wu TC. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 2001; 166:6218-26.
8. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16, E7 epitope. Am J Obstet Gynecol 1996; 175:1586-93.
9. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57:2943-50.
10. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 1997; 57:4855-61.
11. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ. Induction of human papillomavirus-specific CD4 (+) and CD8 (+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999; 73:5402-10.
12. Higgins GD, Uzelin DM, Phillips GE, McEvoy P, Marin R, Burrell CJ. Transcription patterns of human papillomavirus type 16 in genital intraepithelial neoplasia: evidence for promoter usage within the E7 open reading frame during epithelial differentiation. J General Virol 1992; 73:2047-57.
13. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990; 46:1029-34.
14. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 1994; 15:464-9.
15. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96.
16. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996; 183:7-11.
17. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
18. Ting YMM. Detection and typing of genital human papilloma-viruses. In: G D Innis, MA Sninsky, JJ, eds. PCR Protocols, A Guide to Methods and Applications. San Diego: Academic Press, 1990:356-67.
19. Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol 1991; 72:1039-44.
20. Sacerdote P, Rubboli F, Locatelli L, Ciciliato I, Mantegazza P, Panerai AE. Pharmacological modulation of neuropeptides in peripheral mononuclear cells. J Neuroimmunol 1991; 32:35-41.
21. Simon MM, Waring P, Lobigs M, Nil A, Tran T, Hla RT, Chin S, Mullbacher A. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J Immunol 2000; 165:3663-72.
22. Ressing ME, Sette A, Brandt RM et al. Human CTL epitopes encoded by human papillomavirus type 16, E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154:5934-43.
23. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991; 173:1007-15.
24. Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165:1705-11.
25. Cheng WF, Hung CF, Hsu KF et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 2001; 12:235-52.
26. + T cells using an ELISPOT assay. J Immunol Methods 1995; 181:45-54.
27. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8:177-7.
28. Cheng WF, Hung CH, Chai CY, Hsu KF, He L, Ling M, Wu TC. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 2001; 75:2368-76.
29. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002; 13:553-68.
30. Schoell WM, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE.Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16, E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. Gynecol Oncol 1999, 74: 448-55.
31. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347: 523-7.
32. Helmerhorst TJ, Meijer CJ. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002; 12:235-6.
33. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14:178-82.
34. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000; 19:6673-9.
35. Simon RM, Steinberg SM, Hamilton M et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19:1848-54.
36. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302.
37. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
38. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
39. Lee J. The HLA System: a New Approach. New York: Springer-Verlag, 1990.
40. Shen SW, Hu CY, Lin CY, Yang YC, Hsieh RP. Human leukocyte antigen polymorphisms in the Taiwanese population. J Formos Med Assoc 1999; 98:11-8.
41. Bourgault Villada I, Beneton N, Bony C et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000; 30:2281-9.
42. van der Burg SH, Ressing ME, Kwappenfaerg KM et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91:612-8.
43. Nonn M, Schinz M, Zumfaach K, Pawlita M, Schneider A, Durst M, Kaufmann AM. Dendritic cell-based tumor vaccine for cervical cancer I. In vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 2003; 129:511-20.